146 related articles for article (PubMed ID: 15994934)
41. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells.
Carramusa L; Contino F; Ferro A; Minafra L; Perconti G; Giallongo A; Feo S
J Cell Physiol; 2007 Nov; 213(2):511-8. PubMed ID: 17503467
[TBL] [Abstract][Full Text] [Related]
42. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
43. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
44. MYC and the control of DNA replication.
Dominguez-Sola D; Gautier J
Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890833
[TBL] [Abstract][Full Text] [Related]
45. c-MYC-induced genomic instability.
Kuzyk A; Mai S
Cold Spring Harb Perspect Med; 2014 Apr; 4(4):a014373. PubMed ID: 24692190
[TBL] [Abstract][Full Text] [Related]
46. Taming of the beast: shaping Myc-dependent amplification.
Wolf E; Lin CY; Eilers M; Levens DL
Trends Cell Biol; 2015 Apr; 25(4):241-8. PubMed ID: 25475704
[TBL] [Abstract][Full Text] [Related]
47. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.
Oran AR; Adams CM; Zhang XY; Gennaro VJ; Pfeiffer HK; Mellert HS; Seidel HE; Mascioli K; Kaplan J; Gaballa MR; Shen C; Rigoutsos I; King MP; Cotney JL; Arnold JJ; Sharma SD; Martinez-Outschoorn UE; Vakoc CR; Chodosh LA; Thompson JE; Bradner JE; Cameron CE; Shadel GS; Eischen CM; McMahon SB
Oncotarget; 2016 Nov; 7(45):72395-72414. PubMed ID: 27590350
[TBL] [Abstract][Full Text] [Related]
48. CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth.
Jiménez-P R; Martín-Cortázar C; Kourani O; Chiodo Y; Cordoba R; Domínguez-Franjo MP; Redondo JM; Iglesias T; Campanero MR
Haematologica; 2018 Oct; 103(10):1669-1678. PubMed ID: 29880607
[TBL] [Abstract][Full Text] [Related]
49. c-myc expression: keep the noise down!
Chung HJ; Levens D
Mol Cells; 2005 Oct; 20(2):157-66. PubMed ID: 16267388
[TBL] [Abstract][Full Text] [Related]
50. Converging disease genes in ICF syndrome: ZBTB24 controls expression of CDCA7 in mammals.
Wu H; Thijssen PE; de Klerk E; Vonk KK; Wang J; den Hamer B; Aytekin C; van der Maarel SM; Daxinger L
Hum Mol Genet; 2016 Sep; 25(18):4041-4051. PubMed ID: 27466202
[TBL] [Abstract][Full Text] [Related]
51. The c-myc story: where we've been, where we seem to be going.
Potter M; Marcu KB
Curr Top Microbiol Immunol; 1997; 224():1-17. PubMed ID: 9308224
[No Abstract] [Full Text] [Related]
52. Tumorigenesis: Megaphone MYC.
McCarthy N
Nat Rev Cancer; 2012 Nov; 12(11):733. PubMed ID: 23037452
[No Abstract] [Full Text] [Related]
53. JPO1/CDCA7, a novel transcription factor E2F1-induced protein, possesses intrinsic transcriptional regulator activity.
Goto Y; Hayashi R; Muramatsu T; Ogawa H; Eguchi I; Oshida Y; Ohtani K; Yoshida K
Biochim Biophys Acta; 2006; 1759(1-2):60-8. PubMed ID: 16580749
[TBL] [Abstract][Full Text] [Related]
54. The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation.
Gill RM; Gabor TV; Couzens AL; Scheid MP
Mol Cell Biol; 2013 Feb; 33(3):498-513. PubMed ID: 23166294
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
56. CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle.
Wang H; Ye L; Xing Z; Li H; Lv T; Liu H; Zhang F; Song Y
Pathol Res Pract; 2019 Nov; 215(11):152559. PubMed ID: 31570276
[TBL] [Abstract][Full Text] [Related]
57. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
58. CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion.
Martín-Cortázar C; Chiodo Y; Jiménez RP; Bernabé M; Cayuela ML; Iglesias T; Campanero MR
Haematologica; 2020 Mar; 105(3):730-740. PubMed ID: 31221787
[TBL] [Abstract][Full Text] [Related]
59. CDCA7 and HELLS mutations undermine nonhomologous end joining in centromeric instability syndrome.
Unoki M; Funabiki H; Velasco G; Francastel C; Sasaki H
J Clin Invest; 2019 Jan; 129(1):78-92. PubMed ID: 30307408
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
